Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lucie Lepine"'
Autor:
Pier Luigi Zinzani, Anna Sureda, Cecilia Carpio, Krimo Bouabdallah, Robin Meng, Guillaume Cartron, Marjolein van der Poel, Su-Peng Yeh, Raul Cordoba, Alessandro Re, Armando López-Guillermo, Lucie Lepine, Youngil Koh, Steven Le Gouill, Giovanni Abbadessa, Luís Francisco Araújo, Vincent Ribrag, Martine E D Chamuleau, Olivier Casasnovas, Ran Ji, Rao Saleem, Won Seog Kim, Maria Ilidia Moreira, Daniela Alves, Carmelo Carlo-Stella
Publikováno v:
Hematological Oncology, 41(1), 108-119. Wiley
Scientia
Carlo-Stella, C, Zinzani, P L, Sureda, A, Araújo, L, Casasnovas, O, Carpio, C, Yeh, S-P, Bouabdallah, K, Cartron, G, Kim, W S, Cordoba, R, Koh, Y, Re, A, Alves, D, Chamuleau, M, le Gouill, S, López-Guillermo, A, Moreira, I, van der Poel, M W M, Abbadessa, G, Meng, R, Ji, R, Lépine, L, Saleem, R & Ribrag, V 2022, ' A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma ', Hematological Oncology . https://doi.org/10.1002/hon.3089
Hematological Oncology. John Wiley and Sons Ltd
Scientia
Carlo-Stella, C, Zinzani, P L, Sureda, A, Araújo, L, Casasnovas, O, Carpio, C, Yeh, S-P, Bouabdallah, K, Cartron, G, Kim, W S, Cordoba, R, Koh, Y, Re, A, Alves, D, Chamuleau, M, le Gouill, S, López-Guillermo, A, Moreira, I, van der Poel, M W M, Abbadessa, G, Meng, R, Ji, R, Lépine, L, Saleem, R & Ribrag, V 2022, ' A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma ', Hematological Oncology . https://doi.org/10.1002/hon.3089
Hematological Oncology. John Wiley and Sons Ltd
Introduction: Immune checkpoint blockade of programmed death-1 (PD-1) receptor and its ligand (PD-L1) has contributed to efficacy in many tumor types, with clinical responses observed in a proportion of patients (pts) with Hodgkin lymphoma and rare n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::086237dc28c03b5f031a7a993d237717
https://cris.maastrichtuniversity.nl/en/publications/5d163f18-ed7b-45ef-b334-d47a337fea84
https://cris.maastrichtuniversity.nl/en/publications/5d163f18-ed7b-45ef-b334-d47a337fea84
Autor:
Maria-Victoria Mateos, Paula Rodriguez Otero, Youngil Koh, Joaquin Martinez-Lopez, Gurdeep Parmar, H. Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vania T.M. Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Omur G. Sevindik, Tatiana Lavrova, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Mony Morisse, Irene Ghobrial
Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients (pts) with high-risk smolde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a625388b7e086ccf704fd1a7a005cf9
https://hdl.handle.net/20.500.12511/10630
https://hdl.handle.net/20.500.12511/10630
Autor:
Youngil Koh, Lucie Lepine, Miles Prince, Valdas Peceliunas, Sevgi Kalayoglu Besisik, Irene M. Ghobrial, Codina Oprea, Emil Hermansen, Javier de la Rubia, Vania Hungria, Hang Quach, Paula Rodriguez-Otero, Maria-Victoria Mateos, Jin Seok Kim, Christine Devisme, Joaquin Martinez-Lopez, Sandrine Macé, Gurdeep Parmar, Xavier Leleu, Fredrik Schjesvold, Franck Dubin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S109-S110
Background: High-risk smoldering multiple myeloma (HR-SMM) is associated with a greater risk of progression to symptomatic disease, suggesting the need for early, efficacious therapeutic interventions to improve outcomes. The ongoing, randomized Phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c4ca204d08457102b7ca7844f0570c1
https://doi.org/10.1016/s2152-2650(21)02264-3
https://doi.org/10.1016/s2152-2650(21)02264-3
Autor:
Alexander Lesokhin, Richard LeBlanc, Meletios A. Dimopoulos, Marcelo Capra, Carmelo Carlo‐Stella, Lionel Karlin, Jean‐Francois Castilloux, Peter Forsberg, Gurdeep Parmar, Axel Tosikyan, Ludek Pour, Vincent Ribrag, Rossella Ribolla, Al‐Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van deVelde, Laurent Mayrargue, Lucie Lépine, Sandrine Macé, Philippe Moreau
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10254-10266 (2023)
Abstract Background Given the incurable nature of multiple myeloma (MM), efforts are made to improve the efficacy of anti‐CD38 monoclonal antibodies via combinations with other potentially synergistic therapies. This Phase 1/2 trial (NCT03194867) w
Externí odkaz:
https://doaj.org/article/5e8923e3821746dba211ec639b02c19b
Autor:
Rui Wang, Antoine Italiano, Shubham Pant, Johann De Bono, Todd M Bauer, Christophe Massard, Chia-Chi Lin, Roberto Iacovelli, Martin Gutierrez, Mansoor Saleh, Helen Lee, Gennaro Daniele, Paolo Andrea Zucali, Marielle Chiron, Bradley C Carthon, Robin Meng, Giovanni Abbadessa, Marcello Tucci, Wu-Chou Su, Alastair Greystoke, Ying-Chun Shen, Matteo Perrino, Yingwen Dong, Laure Loumagne, Lucie Lépine
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/77a4d7bd1ff24db7bd8825f9ede35742
Autor:
Lucie Lepine, Bonnie Auslander
Publikováno v:
The WAC Journal. 1:82-87
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d8ba3dbef32cc7b17e5c28d2eae0f90
https://doi.org/10.37514/wac-j.1989.1.1.14
https://doi.org/10.37514/wac-j.1989.1.1.14